Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice

European Journal of Immunology

Volumn 46, Issue 3, 2016, Pages 582-592

  Wu, Lei ^a   Diny, Nicola L ^a   Ong, Sufey ^a   Barin, Jobert G ^b   Hou, Xuezhou ^a   Rose, Noel R ^a,b   Talor, Monica V ^b   Čiháková, Daniela ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; GM CSF; IL 17A; IL 23; Myocarditis; Th17

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 23; IL17A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MYOCARDITIS; PATHOPHYSIOLOGY; SPLEEN; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-17; INTERLEUKIN-23; MICE; MYOCARDITIS; SIGNAL TRANSDUCTION; SPLEEN; TH17 CELLS;

EID: 84959319987     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545924     Document Type: Article

References (40)

1. Cooper, L. T., Jr., Myocarditis. N. Engl. J. Med. 2009. 360: 1526-1538.
2. Sagar, S., Liu, P. P. and Cooper, L. T., Myocarditis. Lancet 2011. 379: 738-747.
3. Cihakova, D. and Rose, N. R., Pathogenesis of myocarditis and dilated cardiomyopathy. Adv. Immunol. 2008. 99: 95-114.
4. Greaser, M. L., Stressing the giant: a new approach to understanding dilated cardiomyopathy. J. Mol. Cell. Cardiol. 2009. 47: 347-349.
5. Kindermann, I., Barth, C., Mahfoud, F., Ukena, C., Lenski, M., Yilmaz, A., Klingel, K. et al., Update on myocarditis. J. Am. Coll. Cardiol. 2012. 59: 779-792.
6. Kandolin, R., Lehtonen, J., Salmenkivi, K., Räisänen-Sokolowski, A., Lommi, J. and Kupari, M., Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ. Heart Fail. 2013. 6: 15-22.
7. Cooper, L. T., Hare, J. M., Tazelaar, H. D., Edwards, W. D., Starling, R. C., Deng, M. C., Menon, S. et al., Usefulness of immunosuppression for giant cell myocarditis. Am. J. Cardiol. 2008. 102: 1535-1539.
8. Čiháková, D., Sharma, R. B., Fairweather, D., Afanasyeva, M. and Rose, N. R., Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol. Med. 2004. 102: 175-193.
9. Smith, S. C. and Allen, P. M., Myosin-induced acute myocarditis is a T cell-mediated disease. J. Immunol. 1991. 147: 2141-2147.
10. Sonderegger, I., Röhn, T. A., Kurrer, M. O., Iezzi, G., Zou, Y., Kastelein, R. A., Bachmann, M. F. et al., Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 2006. 36: 2849-2856.
11. Afanasyeva, M., Wang, Y., Kaya, Z., Park, S., Zilliox, M. J., Schofield, B. H., Hill, S. L. et al., Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol. 2001. 159: 193-203.
12. Cihakova, D., Barin, J. G., Afanasyeva, M., Kimura, M., Fairweather, D., Berg, M., Talor, M. V. et al., Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am. J. Pathol. 2008. 172: 1195-1208.
13. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009. 27: 485-517.
14. Gaffen, S. L., Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 2011. 3: 1-7.
15. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L. et al., T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008. 28: 29-39.
16. Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C. et al., Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012. 13: 991-999.
17. Reppert, S., Zinser, E., Holzinger, C., Sandrock, L., Koch, S. and Finotto, S., NFATc1 deficiency in T cells protects mice from experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2015. 45: 1426-1440.
18. Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J. and Littman, D. R., The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006. 126: 1121-1133.
19. O'Connor, R. a., Cambrook, H., Huettner, K. and Anderton, S. M., T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease. Eur. J. Immunol. 2013. 43: 2818-2823.
20. El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.-X. et al., The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011. 12: 568-575.
21. Codarri, L., Gyülvészi, G., Tosevski, V., Hesske, L., Fontana, A., Magnenat, L., Suter, T. et al., RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011. 12: 560-567.
22. Ahern, P. P., Schiering, C., Buonocore, S., McGeachy, M. J., Cua, D. J., Maloy, K. J. and Powrie, F., Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010. 33: 279-288.
23. Abraham, C. and Cho, J. H., IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 2009. 60: 97-110.
24. Zúñiga L. A., Jain, R., Haines, C. and Cua, D. J., Th17 cell development: from the cradle to the grave. Immunol. Rev. 2013. 252: 78-88.
25. Becher, B., Durell, B. G. and Noelle, R. J., IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 2003. 112: 1186-1191.
26. Wu, L., Ong, S., Talor, M. V., Barin, J. G., Baldeviano, G. C., Kass, D. A., Bedja, D. et al., Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J. Exp. Med. 2014. 211: 1449-1464.
27. Baldeviano, G. C., Barin, J. G., Talor, M. V., Srinivasan, S., Bedja, D., Zheng, D., Gabrielson, K. et al., Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ. Res. 2010. 106: 1646-1655.
28. Thakker, P., Leach, M. W., Kuang, W., Benoit, S. E., Leonard, J. P. and Marusic, S., IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 2007. 178: 2589-2598.
29. Wu, C., Yosef, N., Thalhamer, T., Zhu, C., Xiao, S., Kishi, Y., Regev, A. et al., Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013. 496: 513-517.
30. Ogura, H., Murakami, M., Okuyama, Y., Tsuruoka, M., Kitabayashi, C., Kanamoto, M., Nishihara, M. et al., Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008. 29: 628-636.
31. Kaieda, S., Shin, K., A, N. P., Seki, K., Lee, R. T., Stevens, R. L. and Lee, D. M., Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J. Biol. Chem. 2010. 285: 21478-21486.
32. Cavallini, N. F., Hu, D., Brisslert, M., Cialic, R., Erlandsson, M. C., Pullerits, R., Kuchroo, V. K. et al., Pathogenic trans-differentiation of Th17 cells contribute to perpetuation of rheumatoid arthritis during anti-TNF treatment. Mol. Med. 2015. 21: 536-543.
33. Burkett, P. R., Meyer, G. and Kuchroo, V. K., Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J. Clin. Invest. 2015. 125: 1-9.
34. Afanasyeva, M., Wang, Y., Kaya, Z., Stafford, E. A., Dohmen, K. M., Sadighi Akha, A. A. and Rose, N. R., Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 2001. 104: 3145-3151.
35. Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H. et al., Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 2011. 12: 255-263.
36. Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S. et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008. 371: 1665-1674.
37. Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E. et al., Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012. 367: 1519-1528.
38. Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R. and Kasper, L. H., Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008. 7: 796-804.
39. Shiomi, A., Usui, T., Ishikawa, Y., Shimizu, M., Murakami, K. and Mimori, T., GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J. Immunol. 2014. 193: 849-859.
40. Aretz, H. T., Billingham, M. E., Edwards, W. D., Factor, S. M., Fallon, J. T., Fenoglio, J. J., Olsen, E. G. et al., Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1987. 1: 3-14.